Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on April 2 and set a price target of CHF135.00. The company’s shares clos...

Novartis AG (NOVN) Gets a Buy from Kepler Capital

President Donald Trump on Thursday signed an executive order to impose a 100% tariff on imported branded medicines (patented drugs and their active...

AZN, NVO, NVS: What Does Trump’s New 100% Tariff Mean for Pharma Giants?

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Novartis AG, with a price target of CHF105.00. Quigley cov...

Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)

Nevada Sunrise Gold ( ($TSE:NEV) ) just unveiled an update. Nevada Sunrise Metals has identified new gold-in-soil anomalies at its Griffon Gold Min...

Nevada Sunrise Uncovers New Gold-in-Soil Targets at Griffon Project

Barclays analyst James Gordon CFA maintained a Hold rating on Novartis AG today and set a price target of CHF120.00. According to TipRanks, Gordon ...

Novartis AG (NOVN) Receives a Hold from Barclays

Barclays analyst James Gordon CFA maintained a Hold rating on Novartis AG yesterday and set a price target of CHF120.00. The company’s shares close...

Barclays Reaffirms Their Hold Rating on Novartis AG (NOVN)

Goldman Sachs analyst James Quigley maintained a Sell rating on Novartis AG today and set a price target of CHF101.00. According to TipRanks, Quigl...

Goldman Sachs Sticks to Their Sell Rating for Novartis AG (NOVN)

Novartis received a Hold rating and price target from Bernstein analyst Justin Smith today. According to TipRanks, Smith is a 4-star analyst with a...

Novartis (NVS) Receives a New Rating from Bernstein

An announcement from Novartis ( ($NVS) ) is now available. On March 18, 2026, Novartis AG filed a Form 6-K in the United States reporting a major U...

Novartis Raises $11 Billion in Multi-Tranche U.S. Bond Offering

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Warby Parker (WRBY) and Annovis Bio (ANVS) with bull...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$154.42	0.00%	2.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$154.42	0%	2.12M
3
4
5
6

NVS

NVS

No Data Available

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel